Search - tctmd.com

Displaying 1 - 20 of 103

Sort: Relevancy | Date

News Daily News

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Michael O'Riordan

January 30, 2026

News Daily News

Cardioprotective Flush, Without Reanimation, Safe and Effective in DCD Transplant

Michael O'Riordan

January 28, 2026

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Features

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

Michael O'Riordan

October 17, 2025

News Conference News ESC 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

Michael O'Riordan

September 01, 2025

News Conference News ESC 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Michael O'Riordan

August 31, 2025

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

No Change in HF Outcomes When Private Equity Buys the Hospital

News Daily News

Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients

Michael O'Riordan

June 16, 2025

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Daily News

Some Mitral TEER Patients Slipping Through the Cracks in the First Month

Michael O'Riordan

March 21, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Michael O'Riordan

March 03, 2025

News Daily News

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

Michael O'Riordan

February 13, 2025

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

Advertisement

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Cardioprotective Flush, Without Reanimation, Safe and Effective in DCD Transplant

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Some Mitral TEER Patients Slipping Through the Cracks in the First Month

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content